HPV Screening Ages for Cervical Cancer Prevention
Begin cervical cancer screening with HPV testing at age 25 years and continue through age 65 years, then discontinue if adequate prior screening is documented. 1
Screening Initiation: Age 25 Years
The American Cancer Society (2020) strongly recommends starting cervical cancer screening at age 25 years with primary HPV testing every 5 years as the preferred strategy 1. This represents a shift from the previous recommendation of age 21 years, based on several critical factors:
- Only 0.8% of cervical cancer cases occur in women aged 20-24 years, compared to 4% in those aged 25-29 years 1
- Cervical cancer deaths attributable to diagnosis at ages 20-24 represent only 0.5% of total deaths, versus 3% for ages 25-29 1
- Women under 25 have extremely high rates of transient HPV infections that naturally regress without intervention
- Treatment of precancerous lesions in younger women carries significant risk of adverse obstetric outcomes 1
The USPSTF (2018) maintains a recommendation to begin at age 21 with cytology alone every 3 years for ages 21-29 2. However, the more recent ACS guideline (2020) provides stronger evidence for delaying initiation to age 25, particularly given the minimal disease burden and high potential for harm from overtreatment in the younger age group.
Screening Ages 25-65 Years
Primary HPV testing every 5 years is the preferred screening method for all individuals aged 25-65 years 1.
Acceptable Alternatives During Transition Period:
- Co-testing (HPV + cytology) every 5 years
- Cytology alone every 3 years
These alternatives are considered acceptable only where FDA-approved primary HPV testing is not yet available, and should be phased out as access improves 1.
Age-Specific Considerations:
Ages 25-29: The ACS recommends primary HPV testing starting at age 25, while USPSTF recommends cytology alone every 3 years for ages 21-29 3. The discrepancy reflects different publication years (ACS 2020 vs USPSTF 2018), with the more recent ACS guideline incorporating newer evidence on HPV testing performance.
Ages 30-65: Both guidelines agree on screening every 3 years with cytology alone, every 5 years with HPV testing alone, or every 5 years with co-testing 1, 2.
Screening Cessation: Age 65 Years
Discontinue all cervical cancer screening after age 65 years if adequate prior screening is documented and no history of CIN 2+ in the past 25 years 1.
Adequate Prior Screening Defined As:
- 2 consecutive negative HPV tests, OR
- 2 consecutive negative co-tests, OR
- 3 consecutive negative cytology tests
All within the past 10 years, with the most recent test within the recommended interval 1.
Important Exception:
Individuals older than 65 years without sufficient documentation of prior screening should continue screening until cessation criteria are met 1.
Critical Implementation Points
Do NOT screen:
- Before age 25 years (ACS) or age 21 years (USPSTF) 1, 2
- After age 65 with adequate prior screening 1
- After hysterectomy with cervix removal (unless history of high-grade lesions) 2
These recommendations apply regardless of:
- Sexual history
- HPV vaccination status
- Gender identity (applies to all individuals with a cervix) 1
Different recommendations apply for high-risk individuals:
- HIV infection
- Immunosuppression
- History of DES exposure in utero
- Prior high-grade cervical lesions or cancer 3
The shift toward primary HPV testing and later screening initiation reflects improved understanding of HPV natural history and aims to maximize cancer prevention while minimizing harms from overdetection and overtreatment of transient infections that would naturally regress.